ESC 365 - Professor Rory Collins

Speaker illustration

Professor Rory Collins

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

Member of:

Rory Collins studied Medicine at London University, and Statistics at George Washington University (USA) and Oxford University. He came to Oxford in 1981 to run the ISIS “mega-trials” which showed that emergency treatment of heart attacks with streptokinase and aspirin halves mortality. Subsequently, his focus has involved showing that lowering LDL-cholesterol safely reduces the risk of having heart attacks and strokes. In 1985, he became co-director (with Richard Peto) of the University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). He was appointed BHF Professor of Medicine and Epidemiology in 1996, and Head of the Nuffield Department of Population Health in 2013. Rory became Principal Investigator of the UK Biobank prospective study of 500,000 people in 2005. He was elected to the Fellowship of the UK Academy of Medical Science in 2004 and the Royal Society in 2015, and knighted by the Queen for services to Science in 2011.

Sessions Presentations Articles

Latest science in COVID and vaccination

Event: ESC Congress 2022

Topic: European Society of Cardiology

Session type: Late-Breaking Science

Statistics and interpretation of clinical trials

Event: ESC Congress 2022

Topic: Research Methodology

Session type: Cardiology Toolbox

Cardiovascular epidemiology & trial design

Event: ESC Congress 2022

Topic: Cardiovascular Epidemiology

Session type: Abstract Sessions

UK Biobank: a unique global platform for cardiovascular discovery science

Event: ESC Congress 2022

Topic: Biostatistics

Session type: Symposium

Hot Line DAPA-CKD

Event: ESC Congress 2020

Topic: Renal Failure and Cardiovascular Disease

Session type: Hot Line

m-Health and other

Event: Digital Health 2019

Topic: Remote Patient Monitoring and Telehealth, Other

Session type: Pitch Session

Targeting inflammation in cardiovascular disease - Is it feasible? And safe?

Event: ESC Congress 2019

Topic: Pharmacology and Pharmacotherapy

Session type: Symposium

Late Breaking Registry Results 2

Event: ESC Congress 2018

Topic: Other

Session type: Late-Breaking Science

Making an impact: optimal secondary prevention following acute coronary syndromes

Event: ESC Congress 2017

Topic: Adjunctive medical therapy

Session type: Expert Advice

New insights in statin therapy

Event: ESC Congress 2017

Topic: Drug therapy

Session type: Advances in Science

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources